Company intelligence / Profile preview

NervGen Pharma Corp.

Vancouver, British Columbia, Canadanervgen.com ↗

Ownership: Public · NGEN
Development stage: Phase 2

Overview

NervGen’s lead candidate, NVG‑291, has completed enrollment in the chronic cohort and begun enrollment in the subacute cohort of a Phase 1b/2a proof-of-concept clinical trial for spinal cord injury. Topline data from the chronic cohort are expected June 2025. An expanded access protocol has been initiated for eligible SCI patients who participated in prior trials. Preclinical candidate NVG‑300 shows promising activity in models of ischemic stroke and SCI.[4][6]

Therapeutic areas: CardiovascularNeurology
Modalities: Peptides (therapeutic peptide NVG-291)[9]Small molecules/peptide analogs (NVG-300, preclinical)[1][7]
Industry: Biotech

Drug pipeline

4 assets

NVG-291

3 more assets in the full pipeline.

Request access →

Partnerships

Technology licensed from Case Western Reserve University; no major pharma partnerships disclosed as of May 2025.[9]

Financials

Market cap: $175.1M
Total revenue: $0
Enterprise value: $88.1M

Beyond the preview

Go deeper on NervGen Pharma Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NervGen Pharma Corp..

Explore the full profile